alexa Capecitabine-induced Toxicity: An Outcome Study into Dr
ISSN: 2329-6771

Journal of Integrative Oncology
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Capecitabine-induced Toxicity: An Outcome Study into Drug Safety

Janneke Baan1, Monique MEM Bos2*, Savita U Gonesh-Kisoensingh3, Iwan A Meynaar4, Jelmer Alsma5, Erik Meijer6 and Arnold GVulto7

1Albert Schweitzer Hospital, Department of Medicine, Dordrecht, The Netherlands

2Reinier de Graaf Group of Hospitals, Department of Medicine, The Netherlands

3Saint Lucas Andreas Hospital, Hospital Pharmacy, Amsterdam, The Netherlands

4HAGA Hospital, Intensive Care Unit, Den Hague, The Netherlands

5Erasmus University Medical Center, department of Internal Medicine, Rotterdam, The Netherlands

6Reinier de Graaf Group of Hospitals, Hospital Pharmacy, Delft, The Netherlands

7Erasmus University Medical Center, Hospital Pharmacy, Rotterdam, The Netherlands

*Corresponding Author:
Monique MEM Bos
Reinier de Graaf Group of Hospitals
Reinier de Graaf weg 3-11, 2625 AD Delft, The Netherlands
Tel: 0031-15-2603165/3101
Fax: 0031-15-2603116
E-mail: [email protected]

Received date January 16, 2014; Accepted date February 25, 2014; Published date March 05, 2014

Citation: Baan J, Bos MMEM, Gonesh-Kisoensingh SU, Meynaar IA, Alsma J, et al. (2014) Capecitabine-induced Toxicity: An Outcome Study into Drug Safety. J Integr Oncol 3:113. doi:10.4172/2329-6771.1000113

Copyright: © 2014 Baan J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: The use of capecitabine has risen exponentially in the Netherlands since 2001. Clinical trials describe a mild toxicity profile. Because circumstances in daily clinical practice can differ a lot from clinical trial setting, we performed this retrospective analysis in a large community hospital to verify toxicity in a clinical situation.

Methods: A retrospective cohort study was conducted in patients with malignancies of the gastrointestinal tract or breast treated with capecitabine in the period of January 2007 to January 2009. Primary study endpoint was the incidence and severity of capecitabine-induced toxicity in daily clinical practice. Secondary endpoint concerned determination of risk factors for toxicity due to capecitabine.

Results: Of 281 patients 92% experienced some degree of toxicity. Grade 3-4 toxicity occurred in 30% of patients receiving monotherapy and in 47% with combination therapy. This was in accordance with the literature. Type of toxicity varied, but gastro intestinal symptoms and hand foot syndrome were most commonly found. Risk of toxicity increased with increasing age, independently of creatinine clearance.

Conclusions: Therapy with capecitabine monotherapy or capecitabine containing regiments in daily clinical practice is accompanied by considerable toxicity, but frequency and severity are consistent with published clinical trials. More toxicity can be expected with increasing age.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords